Can you share with our readers key highlights of Lambda Therapeutic Research (Lambda)’s operations since 2019?

Lambda Novum Therapeutic Research is among the world’s leading CROs, providing full spectrum drug development services to the global Big pharma, innovator, biopharmaceutical and generic industries. The company is headquartered in Ahmedabad – India, with facilities and operations in Mehsana (India), London (UK), Pittsburgh (USA), and Las Vegas (USA). Every day, over 1,500 employees collaborate in perfect harmony to take revolutionary leaps in life sciences.

Lambda Novum is a market leader in both early phase and late phase clinical research activities. The company’s overall focus remains on the late phase oncology studies both in new entities as well as NDDS molecules, biosimilars and of course pharmacovigilance, as we consolidate our undisputed leadership in the BA/BE segment.

Our cutting edge infrastructure, capabilities to conduct global multi-centric trials across various therapeutic domains, complex NCE studies and early phase studies, complex Biosimilar trials, and advanced digital platforms are but some of our differentiators.

Are there any therapeutic areas or client profiles that Lambda has seen an uptick in demand from?

From a client perspective, we have seen an uptick on the number of research projects and clinical trials being carried out for a mix of Innovator, biotech and generic clients from both the US and Europe.

There has also been an increased demand from generic clients to submit dossiers to EMENA and South Asia markets like Malaysia, China and Thailand, along with LatAm countries like Brazil.

What is Lambda’s value proposition as a research partner with a presence in both North America and India?

Novum enjoys a fairly enviable reputation of being the front-runner in the dermatology domain over the last 25 years in the US CRO industry, and we now hope to further build upon the same by building up capabilities in the oncology and biosimilar late phase clinical trials domains. We have now consolidated operations of both our entities under the single umbrella of Novum Pharmaceutical Research Services in the North American markets.

Novum was a strategic fit for Lambda as it provided a natural platform for growth in the US. This combined entity of Lambda Novum helped scale up our operations and create one of the largest and most comprehensive offerings of on-demand and on-premise solutions to our global clients.

Are there any innovation areas within India’s life sciences ecosystem that excite you most?

We have been front-runners in adopting most of the technological advancements including machine learning and artificial intelligence to the extent possible, which helps in faster regulatory submissions and approvals. This is the value addition that both Indian as well as global clients expect in the present environment and we are well positioned today to meet the same.

What are your strategic objectives for Lambda’s growth over the next few years?

The company is currently aiming at revenues of US$130 million by the year FY 2025-26 and growing at a CAGR of 28% YoY. We have one of the industry's finest credit ratings, which speaks much about our financial health. This enables us to pursue other M&As in the near future for our late phase clinical trials unit, biosimilar labs, and pharmacovigilance divisions, which will propel our growth even further.

Our vision is to continuously improve and adopt technological advancements which suit the pharmaceutical industry. Lambda Novum enjoys a fairly enviable reputation of being the front-runner in the Dermatology domain over the last 25 years in the US CRO industry, and we aim to further build upon the same by building up capabilities in the oncology and biosimilar late phase clinical trials domains.